The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Toy, Elaine ^a   Balasubramanian, Sripriya ^b   Selmi, Carlo ^c,d   Li, Chin Shang ^e   Bowlus, Christopher L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholangiocarcinoma; Epidemiology; Inflammatory bowel disease; Transplantation

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CAUCASIAN; CHILD; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; SCHOOL CHILD; SEX DIFFERENCE; SODIUM BLOOD LEVEL; UNITED STATES; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; PATHOLOGY; SCLEROSING CHOLANGITIS; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CHILD; CHOLANGITIS, SCLEROSING; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 79960557672     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-83     Document Type: Article

References (38)

1. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005, 4(3):137-143. 10.1016/j.autrev.2004.09.003, 15823499.
2. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51(2):237-267. 10.1016/j.jhep.2009.04.009, 19501929.
3. Faubion WA, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001, 33(3):296-300. 10.1097/00005176-200109000-00013, 11593125.
4. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54(1):91-96. 10.1136/gut.2004.046615, 1774346, 15591511.
5. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996, 110(5):1496-1502. 10.1053/gast.1996.v110.pm8613055, 8613055.
6. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002, 51(4):567-573. 10.1136/gut.51.4.567, 1773401, 12235082.
7. van Erpecum KJ, Smits SJ, van de Meeberg PC, Linn FH, Wolfhagen FH, vanBerge-Henegouwen GP, Algra A. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996, 110(5):1503-1506. 10.1053/gast.1996.v110.pm8613056, 8613056.
8. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, Ciusani E, Chapman R, Ercilla G, Fausa O, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999, 53(5):459-469. 10.1034/j.1399-0039.1999.530502.x, 10372541.
9. Karlsen TH, Boberg KM, Vatn M, Bergquist A, Hampe J, Schrumpf E, Thorsby E, Schreiber S, Lie BA. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun 2007, 8(3):275-278. 10.1038/sj.gene.6364377, 17301827.
10. Bittencourt PL, Palacios SA, Cancado EL, Carrilho FJ, Porta G, Kalil J, Goldberg AC. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism. Gut 2002, 51(4):609-610. 10.1136/gut.51.4.609, 1773373, 12235090.
11. Neri TM, Cavestro GM, Seghini P, Zanelli PF, Zanetti A, Savi M, Podda M, Zuin M, Colombo M, Floreani A, et al. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis 2003, 35(8):571-576. 10.1016/S1590-8658(03)00274-3, 14567462.
12. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: Unique clinical and HLA associations. Liver Transplantation 2010,
13. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Yawn BP, Dickson ER, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125(5):1364-1369. 10.1016/j.gastro.2003.07.011, 14598252.
14. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33(1):99-103. 10.1080/00365529850166284, 9489916.
15. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007, 102(5):1042-1049. 10.1111/j.1572-0241.2007.01103.x, 17313496.
16. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126(7):1929-1930. 10.1053/j.gastro.2004.04.052, 15188211.
17. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008, 48(6):939-944. 10.1016/j.jhep.2008.02.017, 18433916.
18. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010, 52(2):571-577. 10.1002/hep.23678, 20683956.
19. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002, 17(8):908-913. 10.1046/j.1440-1746.2002.02835.x, 12164967.
20. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996, 8(7):685-691.
21. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994, 21(5):787-791. 10.1016/S0168-8278(94)80240-8, 7890895.
22. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002, 97(9):2402-2407. 10.1111/j.1572-0241.2002.06019.x, 12358264.
23. Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, Vaiphei K, Singh K, Dilawari JB. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol 1996, 11(5):429-433. 10.1111/j.1440-1746.1996.tb00286.x, 8743914.
24. Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004, 29(3):153-159. 10.1016/j.hepres.2004.03.006, 15203079.
25. Kamisawa T, Egawa N, Tsuruta K, Okamoto A, Funata N. Primary sclerosing cholangitis may be overestimated in Japan. J Gastroenterol 2005, 40(3):318-319. 10.1007/s00535-004-1543-2, 15830296.
26. Kelly P, Patchett S, McCloskey D, Alstead E, Farthing M, Fairclough P. Sclerosing cholangitis, race and sex. Gut 1997, 41(5):688-689. 10.1136/gut.41.5.688, 1891575, 9414979.
27. Simsek H, Schuman BM. Inflammatory bowel disease in 64 black patients: analysis of course, complications, and surgery. J Clin Gastroenterol 1989, 11(3):294-298. 10.1097/00004836-198906000-00010, 2787820.
28. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006, 101(5):1012-1023. 10.1111/j.1572-0241.2006.00504.x, 16696785.
29. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992, 82(5):703-710. 10.2105/AJPH.82.5.703, 1694121, 1566949.
30. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol 2007, 102(7):1429-1435. 10.1111/j.1572-0241.2007.01215.x, 17437504.
31. Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med 1991, 10(3):457-462. 10.1002/sim.4780100317, 2028128.
32. Karlsen TH, Hampe J, Wiencke K, Schrumpf E, Thorsby E, Lie BA, Broome U, Schreiber S, Boberg KM. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol 2007, 102(1):115-121. 10.1111/j.1572-0241.2006.00928.x, 17100974.
33. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990, 11(1):7-11. 10.1002/hep.1840110103, 2295474.
34. Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, Ryden BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991, 100(5 Pt 1):1319-1323.
35. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997, 40(4):451-456. 10.1007/BF02258391, 9106695.
36. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005, 20(3):366-370. 10.1111/j.1440-1746.2005.03727.x, 15740478.
37. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol 2008, 103(8):1998-2006. 10.1111/j.1572-0241.2008.01960.x, 18796097.
38. Hiatt RA, Kaufman L. Epidemiology of inflammatory bowel disease in a defined northern California population. West J Med 1988, 149(5):541-546. 1026530, 3250100.